DLX5 and lung cancer: DLX5 is methylated in early stage lung cancers [91], suggesting that it is only deregulated in lung cancer progression, and it is not in PAH (Table 1), in which it induces the expression of MYC and β-catenin, promoting cell proliferation and metastasis (Figure 10) [92].